Appendix 3B

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the issue of 750,000 options issued to Peloton Capital for Corporate Advisory Services, as announced to the market on 29th August 2018.

Please click here to view the ASX announcement.

Initial Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3X, advising the ASX that Jane Ryan was appointed a director as of 1 September 2018.

Please click here for the ASX announcement.

Initial Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3X, advising the ASX that Sue MacLeman was appointed a director as of 1 September 2018.

Please click here for the ASX announcement.

Final Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3Z, advising the ASX that Paul Grujic ceased to be a director as of 31 August 2018.

Please click here for the ASX announcement.

Appendix 4E Financial Report FY18

Anatara Lifesciences is pleased to release its Appendix 4E Annual Financial Report for the year ended 30 June 2018.

Please click here to view the ASX announcement.

Anatara announces Sue MacLeman appointed Non-Executive Chairman; Jane Ryan as Non-Executive Director and Peloton as corporate advisor

Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of two human health focused directors to the Anatara Lifesciences Board of Directors, with Sue MacLeman joining as Non-Executive Chairman and Dr. Jane Ryan as Non-Executive Director from September 1, 2018.

Please click here for the ASX announcement.

Anatara’s Dr Tracey Mynott leaves to pursue humanitarian applications

Anatara Lifesciences Ltd announces the departure of Dr Tracey Mynott, Chief Scientific Officer. Tracey is a co-founder of Anatara and an inventor of Anatara’s Detach technology. Following the development and successful licensing of Detach to Zoetis, Tracey has made the decision to leave Anatara to pursue her long-standing passion to develop the technology to control infectious diarrhoea in developing countries.

Please click here for the ASX announcement.

Change in Substantial Holding

Form 604 – Notice Of Change Of Interests Of Substantial Holder was released to the ASX on 17th August 2018.

Please click here to view the ASX announcement.

New PAC Partners Research Report

PAC Partners Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

Restore human gut health with GaRP

Please open the attached PDF to view the report.

Appendix 4C Quarterly Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 June 2018.

Please click here to view the ASX announcement.

Investor Presentation and Strategy Update

Anatara is pleased to release its latest presentation and strategy update that will be delivered to institutional investors this week. 

Please click here to view the ASX announcement.

Letter to shareholders

Anatara is pleased to release a copy of a letter from Chairman, Dr Jay Hetzel, to shareholders which accompanies the investor presentation released today.
 
Please click here to view the ASX announcement.

Change of Director’s Notice

Anatara Lifesciences have issued an Appendix 3Y notifying the market of a change in Director’s interest for Mr Iain Ross.

Please click here to view the ASX announcement.

Change of Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3Y notifying the market of a change in Director’s interest for Dr Jay Hetzel.

Please click here to view the ASX announcement.

Final Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3Z, advising the ASX that Dr Mel Bridges ceased to be a director as of 17 May 2018.

Please click here for the ASX announcement.

Anatara CEO Dr Mel Bridges announces retirement

Anatara Lifesciences Ltd (ASX: ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.

Please click here for the ASX announcement.

Investor Presentation on Exclusive Global License Agreement with Zoetis

Anatara releases investor presentation containing structure and terms of its recently announced exclusive global license agreement for lead product, Detach® with Zoetis Inc., the leading global animal health company.

Please click here for the ASX announcement.

Exclusive Global License Agreement with Zoetis

Anatara Lifesciences is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach® as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Please click here for the ASX announcement.

Trading Halt

The securities of Anatara Lifesciences have been placed in Trading Halt Session State at the request of the Company, pending a release of an announcement by the Company.

Please click here for the ASX announcement.

Appendix 4C Quarterly Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 March 2018.

Please click here to view the ASX announcement.

Appendix 4D Half-year Report

Anatara Lifesciences is pleased to release its Appendix 4D Financial Report for the half year ended 31 December 2017.

Please click here to view the ASX announcement.

FDA Approves Human Food Safety section of dossier

Anatara Lifesciences has achieved a significant milestone in the United States of America after receiving a “complete” letter from the US Food and Drug Administration (FDA) for the Technical Section of its Human Food Safety (HFS) submission.

Please click here to view the ASX announcement.

Appendix 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 December 2017.

Please click here to view the ASX announcement.

Anatara receives $1.23m R&D Tax Refund

Anatara Lifesciences is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government’s Research and Development (R&D) Tax Incentive scheme.

Please click here to view the ASX announcement.

Appendix 3B – New Issue Announcement

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the issue of 36,000 options issued to staff under the Anatara Executive Option Plan.

Please click here to view the ASX announcement.

Change in Substantial Holding

Form 604 – Notice Of Change Of Interests Of Substantial Holder was released to the ASX on 14th November 2017.

Please click here to view the ASX announcement.

Annual General Meeting 2017 Results

Anatara Lifesciences is pleased to announce the following results from the Annual General Meeting held on 13th November 2017.

At today’s Annual General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Chairman’s Address and AGM Presentation

Anatara Lifesciences is pleased to release the presentation and Chairman’s address provided to shareholders at the Annual General Meeting held today, 13th November 2017.

Please click here to view the AGM presentation.

Please click here for a copy of the Chairman’s Address.

Appendix 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 September 2017.

Please click here to view the ASX announcement.

Anatara Investor Presentation

Anatara Lifesciences is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Please click here to view the ASX announcement and presentation.

Notice of General Meeting & Proxy Form

Anatara Lifesciences is pleased to release its Notice of General Meeting and Proxy Form for shareholders.

Please click here for the ASX announcement.

Dr Tracey Mynott to speak at the TRI Science Business Inspiration Series

Anatara Lifesciences CSO, Dr Tracey Mynott, will speak at the first session of the Science Business Inspiration Series next week.

SESSION 1 – THE WHOLE JOURNEY: FROM IDEA TO REALITY

For more information click here.

Appendix 4G and Corporate Governance Statement

Anatara Lifesciences is pleased to release its Appendix 4G and Corporate Governance Statement for shareholders.

Please click here for the ASX announcement.

Annual Report to Shareholders

Anatara is pleased to release its 2017 Annual Report to its shareholders.

Please click here for the ASX announcement.

Anatara Extends Pork CRC Options

Anatara Lifesciences has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre (CRC) in 2015.

Please click here to view the ASX announcement.

Preliminary Final Report

Anatara Lifesciences today released its Appendix 4E and financial report for the year ending 30th June 2017.

Please click here to view the ASX announcement.

Anatara and Zoetis to negotiate terms of Detach® Commercial Agreement

Anatara Lifesciences is pleased to announce that global animal health company, Zoetis Inc. (‘Zoetis’) has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach®, with terms to be agreed.

Please click here to view the ASX announcement.

Anatara Lifesciences Trading Halt

The securities of Anatara Lifesciences have been placed in Trading Halt Session State at the request of the Company, pending a release of an announcement by the Company.

Please click here to view the ASX announcement.

PAC Partners initiates analyst coverage on Anatara Lifesciences

This month PAC Partners initiated analyst coverage on Anatara Lifesciences.

PAC has initiated coverage with a Buy rating and price target of $1.36/share.

To download the full report, please click here.

Anatara 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 June 2017.

Please click here to view the ASX announcement.

NEW Wilsons Research & Valuation Report

NEW Wilsons Research & Valuation Report

Wilsons Equity Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.66 per share.

Still have our nose in this little trough

Please open the attached PDF to view the report.

Investor Update and R&D Tax Rebate

Anatara Lifesciences is pleased to provide investors with an update on recent progress.

Please click here to view the ASX announcement.

Update to Anatara 4C Quarterly Report

Anatara Lifesciences wishes to update the description of item 1.8 in the Company’s Appendix 4C for the period ending 31 March 2017, which was released to market this morning.

Please click here to view the ASX announcement and updated quarterly report.

Anatara 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 March 2017.

Please click here to view the ASX announcement.

ABC Landline Story “How pineapples could protect piglets from infection”

Diarrhoea can be deadly in pig farming. Scour, as it’s called in the industry, kills tens of thousands of piglets every year. It’s traditionally been treated with antibiotics, but a Queensland scientist has developed a powerful, natural alternative from an extract found in pineapple stems

The full story on Anatara and Detach™ was featured on Landline, today (19/03/17) and can be viewed online here.

Anatara to feature on ABC’s Landline

Very excited that the story of Anatara Lifesciences and our anti-infective product, Detach™ will feature on ABC’s Landline program this Sunday, March 19 at 12pm.

Make sure you tune into see how we plan to help pig farmers across the globe! #anataralifesciences #detach™ #fightpigscour #AMR

View the promotional video here.

Appendix 4D Half-Year Report

Anatara Lifesciences is pleased to release its Appendix 4D Interim Financial Report for the half year ended 31 December 2016.

Please click here to view the ASX announcement.

Anatara receives second Zoetis payment

Anatara Lifesciences is pleased to announce that it has received a second payment under the exclusive Research Evaluation and License Option Agreement with the global animal health company, Zoetis Inc., to explore the utility of Detach™ a non-antibiotic anti-infective product, for use in food production animals.

Please click here to view the ASX announcement.

Anatara 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 December 2016.

Please click here to view the ASX announcement.

NDF Research Research & Valuation Report

NDF Research’s Initiation of Coverage Research & Valuation Report

NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.

Please click here to view the report.

Anatara Investor Update

Anatara Lifesciences is pleased to release its latest investor presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Please click here to view the ASX announcement and presentation.

Annual General Meeting Results

Anatara Lifesciences is pleased to announce the following results from the Annual General Meeting held on 15th November 2016.

At today’s Annual General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Chairman’s Address and AGM Presentation

Anatara Lifesciences is pleased to release the presentation and Chairman’s address provided to shareholders at the Annual General Meeting held on 15th November 2016.

Please click here to view the AGM presentation.

Please click here for a copy of the Chairman’s Address.

Appendix 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 September 2016.

Please click here to view the ASX announcement.

NEW Wilsons Research & Valuation Report

Wilsons has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and 12 month price target of $1.75 per share.

Please open the attached PDF to view the report.

Appendix 3B – New issue announcement

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the release of 12,746,095 fully paid ordinary shares from voluntary escrow.

Please click here to view the ASX announcement.

Notice of General Meeting, Proxy Form & Appendix 4G

Anatara Lifesciences is pleased to release its Notice of General Meeting, Proxy Form and Appendix 4G and Corporate Governance Statement for shareholders.

Please click here for the Notice and Proxy Form, and here for the Appendix 4G and Corporate Governance Statement.

Annual Report to Shareholders

Anatara is pleased to release its 2016 Annual Report to its shareholders.

Please click here for the ASX announcement.

Anatara receives R&D tax refund

Anatara Lifesciences is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara’s 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Please click here for the ASX annnouncement.

Anatara Investor Presentation

Anatara Lifesciences is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Please click here to view the ASX announcement and presentation.

Release of Shares from Voluntary Escrow

Anatara Lifesciences is pleased to announce that in accordance with Listing Rule 3.10A, Anatara Lifesciences Limited advises that 12,746,095 fully paid ordinary shares will be released from escrow on Sunday 16 October 2016.

Please click here to view the ASX announcement.

Anatara Achieves Major Milestone – APVMA Submission

Anatara Lifesciences is pleased to announce that it has lodged its application for approval to register Detach™ with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach™ is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.

Please click here to view the ASX announcement.

Appendix 3Z – Final Directors Interest Notice

Anatara Lifesciences released an Appendix 3Z – Final Director’s Interest Notice, to the ASX on 26th September 2016.

Please click here to view the ASX announcement.

Successful Completion of Target Safety Study

Anatara Lifesciences is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for Detach™, the Company’s lead product for the control of diarrhoea in piglets.

Please click here to view the ASX announcement.

Appendix 4E and Financial Report

Anatara Lifesciences today released its Appendix 4E and annual financial report for the year ending 30th June 2016.

Please click here to view the ASX announcement.

Amended Appendix 4C

Anatara Lifesciences today released its amended Appendix 4C Quarterly Financial Report for the fourth quarter ended 30 June 2016.

Please click here to view the ASX announcement.

Appendix 4C – 4th Quarter

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the fourth quarter ended 30 June 2016.

Please click here to view the ASX announcement.

Anatara Lifesciences features in Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy Class B recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please click here to view the article.

NEW Wilson HTM Research & Valuation Report

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and price target of $1.75 per share.

Please open the attached PDF to view the report.

Anatara Investor Presentation and Update

Anatara Lifesciences is pleased to release its most recent investor presentation and market update.

Please click here to view the ASX announcement and presentation.

Anatara interviewed for The CEO Sessions

Anatara Lifesciences is pleased to release a copy of Dr Mel Bridges, CEO & Chairman, recent interview with the Financial News Network (FNN) as part of the ASX The CEO Sessions in Sydney on 21st June 2016.

Please click here to view the FNN interview and corresponding ASX presentation.

Appendix 3Y – Change of Director’s Interest Notice

Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 1st July 2016.

Please click here to view the ASX announcement.

Appendix 3Y – Change of Director’s Interest Notice

Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 29th June 2016.

Please click here to view the ASX announcement.

Anatara Expands Executive Team

Anatara Lifesciences announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.

Please click here to view the ASX announcement.

Anatara Trial Update

Anatara Lifesciences wishes to announce it has voluntarily terminated the third efficacy study in Australia for its lead product Detach.

Please click here to view the ASX announcement.

Anatara Investor Presentation

Anatara Lifesciences is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges, will be presenting at both the Finance News Network “The CEO Sessions” and the Gold Coast Investment Showcase this week.

Please click here to view the ASX announcement.

Anatara Market Update – New Trials Commence

Anatara Lifesciences is pleased to release its latest market update to its investors and to announce the commencement of two new trials that will support its application to register Detach™ for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA) and overseas.

Please click here to view the ASX announcement.

NEW Wilson HTM Research and Valuation Report

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a new price target of $1.75 per share.

Please open the attached PDF to view the report.

Appendix 3Y – Change of Director’s Interest Notice

Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 27th April 2016.

Please click here to view the ASX announcement.

Appendix 4C and Updated Cash Balance

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the third quarter ended 31 March 2016.

Please click here to view the ASX announcement.

Anatara Milestone and Market Update

Anatara Lifesciences is pleased to release its most recent milestone and market update to its investors.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Appendix 4D

Anatara Lifesciences is pleased to release its Appendix 4D Interim Financial Report for the half year ended 31 December 2015.

Please click here to view the ASX announcement.

Anatara CSO interviewed for the CommSec Executive Series

CommSec’s Tom Piotrowski speaks with Anatara Lifesciences (ANR) Chief Scientific Officer, Dr Tracey Mynott about its non-antibiotic treatment for gastrointestinal diseases in production animals.

Click here to view the interview.

Investor Update and Managing Director Appointment

Anatara Lifesciences is pleased to release its most recent investor presentation and market update, and to announce that Dr Paul Schober has been appointed as Managing Director effective today.

Please click here to view the ASX announcement and investor presentation.

Appendix 4C – 2nd Quarter

Appendix 4C Financial Report

Anatara Lifesciences has released its Appendix 4C Financial Report, for the 2nd quarter ended 31 December 2015, to the market today.

Please click here to view the ASX announcement.

NEW Wilson HTM Anatara Research & Valuation Report

Wilson HTM has released its fourth research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and increased price target of $1.82 per share.

Please open the attached PDF to view the report.

Anatara Announces Exclusive Research Evaluation and License Option Agreement with Zoetis

Anatara Lifesciences today announced that it has signed an exclusive evaluation and license option agreement with the leading global animal health company Zoetis Inc. for Detach™, Anatara’s non-antibiotic anti-infective product.

Key points:
· Anatara signs an exclusive evaluation and license option agreement with the global animal health company, Zoetis Inc. to explore the utility of Detach™ a non-antibiotic anti-infective product, for use in food production animals
· Detach™ has the potential to play a part as an alternative to traditional antibiotics to control infections in farm animals, as public health officials worldwide seek strategies to combat antimicrobial resistance
· Agreement grants Zoetis an exclusive option to license Detach™ for development and marketing worldwide with Anatara retaining rights to Australia and New Zealand

Please click here to read the ASX announcement.

Appendix 3B – Anatara Executive Option Plan

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM has released its third research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Anatara features in the latest edition of Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please open the attached PDF to view the report.

Appendix 3B

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Annual General Meeting Results

Anatara Lifesciences is pleased to announce the following results from the Annual General Meeting held on 11th November 2015.

At today’s Annual General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Annual General Meeting Presentation

Anatara Lifesciences is pleased to release the presentation provided to shareholders at the Annual General Meeting held on 11th November 2015.

Please click here to view the AGM presentation.

Chairman’s Address to Shareholders

The following Chairman’s address was made to Anatara Lifesciences shareholders at the Annual General Meeting held on 11th November 2015.

Please click here for a copy of the Chairman’s Address.

Appendix 4C – 1st Quarter

Appendix 4C Financial Report

Anatara Lifesciences has released its Appendix 4C Financial Report, for the 1st quarter ended 30 September 2015, to the market yesterday.

Please click here to view the ASX announcement.

Notice of Annual General Meeting and Proxy Form

Anatara Lifesciences is pleased to release its Notice of Annual General Meeting and Proxy Form to shareholders.

Please click here to view the ASX announcement.

Market Update Presentation

Trial Results Support Strong Partnering Interest

Anatara Lifesciences is pleased to release its market update presentation. Executives of the company will be presenting to brokers, analysts and institutional investors over the next two weeks on the company’s progress and track record in delivering against key milestones.

Please click here to view the ASX announcement and investor presentation.

Appendix 3G

Anatara Lifesciences has released an Appendix 3G – Key to Disclosures – Corporate Governance Council Principles and Recommendations.

Please click here to view the ASX announcement.

Anatara Annual Report 2015

Anatara Lifesciences is pleased to release its Annual Report 2015 to shareholders.

Please click here to view the report.